Filing Details
- Accession Number:
- 0001610717-24-000478
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-09-16 16:05:48
- Reporting Period:
- 2024-09-12
- Accepted Time:
- 2024-09-16 16:05:48
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1885522 | Neumora Therapeutics Inc. | NMRA | Biological Products, (No Disgnostic Substances) (2836) | 844367680 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1992908 | A. Robert Lenz | C/O Neumora Therapeutics, Inc. 490 Arsenal Way, Suite 200 Watertown MA 02472 | Head Of R&D | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2024-09-12 | 32,948 | $11.43 | 369,993 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on June 12, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.
- This transaction was executed in multiple trades in prices ranging from $11.22 to $11.6050, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.